Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Undoubtedly ovarian cancer is a vexing, incurable disease for patients with recurrent cancer and therapeutic options are limited. Although the polycomb group gene, Bmi-1 that regulates the self-renewal of normal stem and progenitor cells has been implicated in the pathogenesis of many human malignancies, yet a role for Bmi-1 in influencing chemotherapy response has not been addressed before. Here we demonstrate that silencing Bmi-1 reduces intracellular GSH levels and thereby sensitizes chemoresistant ovarian cancer cells to chemotherapeutics such as cisplatin. By exacerbating ROS production in response to cisplatin, Bmi-1 silencing activates the DNA damage response pathway, caspases and cleaves PARP resulting in the induction apoptosis in ovarian cancer cells. In an in vivo orthotopic mouse model of chemoresistant ovarian cancer, knockdown of Bmi-1 by nanoliposomal delivery significantly inhibits tumor growth. While cisplatin monotherapy was inactive, combination of Bmi-1 silencing along with cisplatin almost completely abrogated ovarian tumor growth. Collectively these findings establish Bmi-1 as an important new target for therapy in chemoresistant ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · cited 1×
“In order to test this we determined phosphorylation levels of Chk2 and H2AX two important biomarkers for DNA damage and activation of the DDR pathway [37].”
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
Park, I.-K., Qian, D., Kiel, M., Becker, M. W., Pihalja, M., Weissman, I. L., Morrison, S. J., & Clarke, M. F. (2003) · Nature · doi:10.1038/nature01587 · Cited by 1,871 · cited 1×
“p16Ink and p19Arf that regulate senescence and apoptosis [47].”
BackgroundBmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452 · cited 1×
“Bmi-1, a polycomb group gene, regulates the proliferative activity of normal stem and progenitor cells [6].”
BackgroundDNA Repair, Genome Stability, and Aging
Lombard, D. B., Chua, K. F., Mostoslavsky, R., Franco, S., Gostissa, M., & Alt, F. W. (2005) · Cell · doi:10.1016/j.cell.2005.01.028 · Cited by 944
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 1×
“Also the increased expression of Bmi-1 was one of the key regulatory factors determining a cellular phenotype captured by the expression of a death-from-cancer signature in a broad spectrum of therapy-resistant clinically lethal malignancies [24].”
BackgroundBmi1 regulates mitochondrial function and the DNA damage response pathway
Liu, J., Cao, L., Chen, J., Song, S., Lee, I. H., Quijano, C., Liu, H., Keyvanfar, K., Chen, H., Cao, L.-Y., et al. (2009) · Nature · doi:10.1038/nature08040 · Cited by 474 · cited 3×
“Recently, it has been reported that neurons, thymocytes and bone marrow cells isolated from Bmi-1 null mice have increased ROS levels than their wild-type counterparts [28,29].”
BackgroundMukhopadhyay, P., Rajesh, M., Haskó, G., Hawkins, B. J., Madesh, M., & Pacher, P. (2007) · Nature Protocols · doi:10.1038/nprot.2007.327 · Cited by 373 · cited 2×
“After washing with HBSS, the cells were incubated with 5 mM carboxy-H2DCFDA (Invitrogen, Carlsbad, CA) [50] in fresh HBSS for 30 min at 37uC.”
Method
Cited by
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Siddique, H. R., & Saleem, M. (2012) · STEM CELLS · doi:10.1002/stem.1035 · Cited by 339
Tissue‐resident macrophages in omentum promote metastatic spread of ovarian cancer
Etzerodt, A., Moulin, M., Doktor, T. K., Delfini, M., Mossadegh-Keller, N., Bajenoff, M., Sieweke, M. H., Moestrup, S. K., Auphan-Anezin, N., & Lawrence, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191869 · Cited by 305
Tumours associated with BAP1 mutations
Murali, R., Wiesner, T., & Scolyer, R. A. (2013) · Pathology · doi:10.1097/pat.0b013e32835d0efb · Cited by 270
Bhattacharyya, S., Saha, S., Giri, K., Lanza, I. R., Nair, K. S., Jennings, N. B., Rodriguez-Aguayo, C., Lopez-Berestein, G., Basal, E., Weaver, A. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079167 · Cited by 254
Self-citation
Metadata
- Authors
- Wang, E., Bhattacharyya, S., Szabolcs, A., Rodriguez-Aguayo, C., Jennings, N. B., Lopez-Berestein, G., Mukherjee, P., Sood, A. K., & Bhattacharya, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-03-21
- Volume
- 6
- Issue
- 3
- Pages
- e17918
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2062800365
- Cited by
- 82
- References
- 7
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.